Frankfurt | Reuters — German mineral miner K+S will cut production of potash fertilizers, dragging core earnings lower, as a halt imposed by China on potash imports dampens global markets. “In the current weak market environment, which is further intensified by the continuing Chinese import bans on the standard potassium chloride product, adjusting production is
K+S cuts output on weak potash demand
Elanco to become No. 2 in animal health with Bayer deal
Reuters — Elanco Animal Health agreed to buy Bayer’s veterinary drugs unit on Tuesday in a cash and stock deal valued at US$7.6 billion (C$10 billion), creating the second largest maker of medicines for livestock and pets and expanding Elanco’s reach online. The deal is the latest in the fast-growing animal health market, which has
Bayer mediator dismisses report of Roundup settlement
New York/Frankfurt | Reuters — Bayer AG has not offered to pay billions of dollars to settle claims in the United States related to the Roundup herbicide, mediator Ken Feinberg said, dismissing a report to that effect which drove its shares as much as 11 per cent higher. “Bayer has not proposed paying $8 billion
Investors call for reprieve for Bayer bosses after AGM rebuke
Frankfurt | Reuters — Three of Bayer’s largest German investors said the drugmaker’s embattled management needed to stay at the helm to avoid further upheaval, despite their unease over a share price slump in the wake of the US$63 billion Monsanto takeover. The backing for CEO Werner Baumann comes after an unprecedented rebuke at the
Bayer shareholders vent ire over Monsanto-linked stock rout
Bonn | Reuters — Bayer shareholders vented their anger over its stock price slump on Friday as litigation risks mount from the German drugmaker’s US$63 billion takeover of seed and chemical firm Monsanto. Several large investors said they will not support aspirin invesotr Bayer’s management in a key vote scheduled for the end of its
Bayer reaps profit lift from Monsanto
Leverkusen, Germany | Reuters –– Bayer’s US$63 billion purchase of seed and chemical firm Monsanto made its mark on the German company’s fourth quarter earnings on Wednesday, lifting profit and boding well for the peak season of its enlarged agriculture business. However, mounting litigation risks related to Monsanto still cast a pall over an adjusted
Bayer to shed animal health division, others after Monsanto deal
Frankfurt | Reuters — Bayer, the German drugmaker that bought U.S. seed company Monsanto, announced on Thursday the sale of its animal health business and a number of others, around 12,000 job cuts and 3.3 billion euros (C$4.98 billion) in impairments. CEO Werner Baumann is under pressure to boost Bayer’s share price after a drop
Ag trade flows may change amid trade dispute, Bayer says
Monheim | Reuters — Bayer said on Tuesday it would be difficult to predict 2019 earnings at its agriculture business, which now includes Monsanto, because a U.S.-Chinese trade dispute could reroute global trade flows in farming commodities. The head of Bayer’s crop science division told Reuters his company could even benefit if U.S. farmers switched
With drugs pipeline in focus, Bayer seen considering cuts
Frankfurt | Reuters — Bayer is considering job cuts and outsourcing as part of a wide-ranging review of drug research and development that will last until at least November, a person familiar with the company told Reuters. The prospect of “very tangible changes” contributed to a decision by key board members to extend the contract
Roundup cancer verdict sends Bayer shares sliding
Frankfurt | Reuters — Bayer shares plunged as much as 14 per cent on Monday, losing about US$14 billion in value, after newly acquired Monsanto was ordered to pay US$289 million in damages in the first of possibly thousands of U.S. lawsuits over alleged links between a weedkiller and cancer. After the verdict
Cyber-Savvy Farmer
